Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.

Globus Medical, Inc. GMED continues to benefit from ... Globus is also optimistic about the recently inked deal to acquire Nevro Corporation. The acquisition of Nevro is expected to expand Globus ...

Globus Medical closed 2024 on a strong note with record financial performance, driven by sales growth, innovative product launches, and strategic acquisitions. The integration of Nevro Corporation ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Globus Medical (GMED – Research Report) and Nevro Corp (NVRO – Research Report). See what stocks are receiving ...

citing the company’s impressive performance and potential synergies from its recent acquisition of Nevro Corp. This acquisition is anticipated to influence Globus Medical’s 2025 financial ...

As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor is the company holding an earnings conference call ...

Fourth-Quarter 2024 Business Highlights and Recent Developments On February 6, 2025, Nevro and Globus Medical (NYSE: GMED) announced that they had entered into a definitive agreement for Globus ...

BTIG responded by raising its price target for Globus Medical shares to $94, maintaining a Buy rating, citing the company’s impressive performance and potential synergies from its recent acquisition ...